Cipla agrees Rifaximin licensing deal
Indian drug maker Cipla has signed a deal with Salix Pharmaceuticals allowing the US-based company exclusive rights relating to the Rifaximin Complexes patent family.
Gilead announces Sovaldi generic deal
US biotechnology company Gilead has agreed a licensing deal with seven Indian drug makers that will enable them to sell a generic version of a drug used to treat hepatitis C.
Epirus, Ranbaxy win Indian approval for arthritis drug
Biopharmaceutical company Epirus has said that India’s drug regulator has approved a biosimilar application to produce a version of a popular arthritis treatment drug.
Pharmaceutical IP under threat from malware, says report
A newly revealed malware could be looking to attack the pharmaceutical sector in order to steal IP, a report has claimed.
Kilpatrick Townsend adds Life sciences specialist to team
Law firm Kilpatrick Townsend & Stockton LLP has bolstered its Californian team with the appointment of a new pharmaceutical IP specialist.
Carpmaels & Ransford hires two new partners to its London office
UK-based law firm Carpmaels & Ransford LLP has announced the appointment of two new partners to its London office.
Bristol-Myers Squibb hits Merck with cancer patent lawsuit
Bristol-Myers Squibb has accused pharmaceutical company Merck of infringing a patent covering a method used to treat cancer.
Australia suggests uprooting plant rights committee
The Australian government department responsible for IP has suggested abolishing a committee that looks after plant breeders’ rights as it looks at alternative means for giving advice to breeders.
Myriad cancer patent upheld in Australia
Companies in Australia will be able to continue to patent human genes after a court rejected an appeal by a breast cancer survivor.
Magistrate judge recommends action in Section 101 case
Magistrate judge Christopher Burke has recommended that the US District Court for the District of Delaware affirm a motion to dismiss a patent infringement case related to the patent eligibility of subject matter, as laid out in 35 USC §101.
